Everest Medicines

News

04 2022/01

Everest Medicines Announces Taiwan FDA Has Accepted New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer
20 2021/12

Everest Medicines and Providence Therapeutics announces that PTX-COVID19-B, a mRNA Vaccine for COVID-19, has received approval for inclusion in WHO Solidarity Trial Vaccines (STV) Program
16 2021/12

Everest Medicines announces FDA grants our Partner Calliditas Therapeutics Accelerated Approval of TARPEYO™ (budesonide) to Reduce Proteinuria in IgA Nephropathy
15 2021/12

Everest Medicines Announces the Acceptance of a New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer in South Korea
01 2021/12

Everest Medicines and Providence Therapeutics Jointly Announce Vaccine Development Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant
24 2021/11

Everest Medicines Announces Inclusion in the MSCI Global Small Cap Indexes - MSCI China Index
11 2021/11

Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients with Metastatic Triple-Negative Breast Cancer Meets Primary Overall Response Rate Endpoint
08 2021/11

Everest Medicines Announces Up to HK$100 million Additional Share Repurchase Program
01 2021/11

Everest Medicines Announces Share Repurchase Transaction Details
29 2021/09

Everest Medicines Initiates Submission of New Drug Application in Hong Kong for Xerava^TM for the Treatment of Complicated Intra-abdominal Infections
24 2021/09

Everest Medicines Announces Approval of Investigational New Drug Application by China NMPA for SPR206
23 2021/09

AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies

Copyright Everest Medicines 2020 云顶药业（苏州）有限公司苏ICP备20038571号 | Terms of Use | Privacy Policy | Disclaimers

沪公网安备 31010602006477号